Alpha Teknova narrowed Q4 2025 free cash flow outflow to negative $0.8 million from negative $1.5 million a year earlier, and full-year free cash flow improved to negative $9.8 million versus negative $13.5 million in 2024. Net loss fell to $4.8 million ($0.09 per share) in Q4 and $17.3 million ($0.32 per share) for 2025, while adjusted EBITDA losses shrank to $1.8 million in Q4 and $6.7 million for the year.

Revenue in Q4 reached $10.0 million, up 8% from $9.3 million, driving full-year sales of $45.0 million, a 7% increase over 2024. Lab Essentials revenue held at $6.8 million in Q4 and rose 7% to $31.0 million for the year, while Clinical Solutions surged 47% to $2.7 million in Q4 and 8% to $7.7 million full-year; active clinical customers spending more than $5,000 annually increased to 60 from 48.

Teknova guided 2026 revenue of $42 million to $44 million, implying about 6% growth at the midpoint, and expects mid-30s gross margins. The company plans to keep free cash outflow under $10 million despite a $2 million increase in sales and marketing investment, shifting from cost cutting to targeted growth ahead of anticipated commercial therapy support by 2027.